Advertisement

Payer

Advertisement

In 2019, Medicare spent roughly $7.7 billion on 10 common diabetes drugs, including GLP-1 medications. By 2023, that amount reached $35.8 billion, marking a 364% increase, according to a new report from HHS' Office of Inspector General. 

Almost 11 million people would become uninsured if Medicaid expansion states can’t fulfill spending obligations left by potential federal Medicaid cuts, according to a Feb. 24 analysis from the Urban Institute and the Robert Wood Johnson Foundation.

Advertisement